Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium

Perevalova, Alina M.; Kobelev, Vyacheslav S.; Sisakyan, Virab G.; Gulyaeva, L. F.; Pustylnyak, Vladimir O.

doi:10.1134/s0006297922110104

Cited by 2 publications

(1 citation statement)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTEN is a major negative regulator of the PI3K/ AKT/mTOR signaling pathway, controlling a wide range of essential cellular processes, including cell proliferation, growth, survival, and metabolism [ 12 , 22 - 24 ]. Considering the biological importance of its function and the profound pathological effects that arise as a consequence of changes in PTEN’s expression levels and/or functionality of the corresponding protein, this vital gene represents a key factor in normal and pathological conditions [ 25 , 26 ]. Regarding its involvement in cancer, it is known that PTEN is one of the most mutated tumor suppressor genes and is often suppressed or downregulated if it is not mutated [ 27 - 30 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies

Boti,

Adamopoulos,

Vassilacopoulou

et al. 2023

View full text Add to dashboard Cite

Background: Phosphatase and tensin homolog, widely known as PTEN, is a major negative regulator of the PI3K/AKT/mTOR signaling pathway, involved in the regulation of a variety of important cellular processes, including cell proliferation, growth, survival, and metabolism. Since most of the molecules involved in this biological pathway have been described as key regulators in cancer, the study of the corresponding genes at several levels is crucial. Objective: Although previous studies have elucidated the physiological role of PTEN under normal conditions and its involvement in carcinogenesis and cancer progression, the transcriptional profile of PTEN has been poorly investigated. Methods: In this study, instead of conducting the “gold-standard” direct RNA sequencing that fails to detect less abundant novel mRNAs due to the decreased sequencing depth, we designed and implemented a multiplexed PTEN-targeted sequencing approach that combined both short- and longread sequencing. Results: Our study has highlighted a broad spectrum of previously unknown PTEN mRNA transcripts and assessed their expression patterns in a wide range of human cancer and non-cancer cell lines, shedding light on the involvement of PTEN in cell cycle dysregulation and thus tumor development. Conclusion: The identification of the described novel PTEN splice variants could have significant implications for understanding PTEN regulation and function, and provide new insights into PTEN biology, opening new avenues for monitoring PTEN-related diseases, including cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies

Boti,

Adamopoulos,

Vassilacopoulou

et al. 2023

View full text Add to dashboard Cite

show abstract

A comparative study of circulating microRNA expression in blood in patients with coronary artery atherosclerosis and thoracic aortic aneurysm

Ngo Bilong,

Vasiliev,

Rozhkov

et al. 2024

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To compare the relative expression levels of circulating microRNAs associated with cardiovascular diseases, selected according to the literature review, in the blood plasma samples of patients with two variants of chronic vascular wall injury: coronary artery atherosclerosis (CAA) and thoracic aortic aneurysm (TAA).Material and methods. Patients admitted to the Clinical Center of the I. M. Sechenov First Moscow State Medical University (University Clinical Hospital No. 1) with CAA (n=45), TAA (n=38), as well as a control group (n=17) were included. Standard clinical and demographic, laboratory and instrumental data were collected in accordance with Russian clinical guidelines, and additional sampling and preparation of blood plasma of patients was carried out with further quantitative determination of the circulating microRNAs level via real-time polymerase chain reaction with reverse transcription. A comprehensive comparative analysis of the profiles of circulating microRNAs in the blood plasma of patients with two different variants of arterial pathology: atherosclerosis and aneurysmal changes, as well as with the control group was carried out. The levels of 12 circulating microRNAs were studied: miR-21-5p, -23a-3p, -29b-3p, -92a-3p, -126-5p, -143-3p, -145-5p, -146a-5p, -150-5p, -181b-5p, 2-23-3p and -451a.Results. The strongest difference with the control group in patients with CAA and TAA was observed for miR-21-5p, -29b-3p and -126-3p. Most of the circulating microRNAs studied were higher in the TAA group compared with CAA and controls these include miR-21-5p, -23a-3p, -29b-3p, -92a-3p, -126-3p, -126-5p, -146a-5p, -150-5p, -181b-5p. Significant differences between the pathology groups were noted for miR-126-3p and miR-205-5p. Some microRNAs (miR-143-3p, -92 a3, -195-5 p) can be used to diagnose coronary artery atherosclerosis, other microRNAs (miR-21-5p, -23a-3p, -126-3p, -126-5p, -451a) are TAA-specific.Conclusion. The present study showed significant differences in the circulating microRNAs in patients with atherosclerotic and aneurysmal lesions of the arteries in comparison with the control group. The most significant difference between norm and pathology was found for miR-21-5p, -29b-5p and -126-3p. The levels of miR-126-3p and -205-5p can be used to differentiate CAA and TAA.

show abstract

Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium

Cited by 2 publications

References 143 publications

Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies

Unraveling the Concealed Transcriptomic Landscape of PTEN in Human Malignancies

A comparative study of circulating microRNA expression in blood in patients with coronary artery atherosclerosis and thoracic aortic aneurysm

Contact Info

Product

Resources

About